June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Eastburn, D.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.

Author:
Eathiraj, S.
Author:
Ebeid, F.
Author:
Ebeling, F.
Author:
Ebina, T.
Author:
Ebrahim, F.
Author:
Eccersley, L.

PS1009 INDIVIDUALIZED FOLLOW-UP IN ADULT ACUTE MYELOID LEUKEMIA USING NGS

Iturri, Z. Blasco; Vazquez, I.; Ariceta, B.; More

HemaSphere. 3(S1):453-454, June 2019.

Author:
Eckert, C.

PF162 FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA

Zaliova, M.; Potuckova, E.; Lukes, J. Jr.; More

HemaSphere. 3(S1):33, June 2019.

Author:
Eclache, V.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

Author:
Economou, M.
Author:
Edahiro, Y.
Author:
eddhib, J.
Author:
Edenfield, W.

S866 PHASE 1/2 TRIAL OF ACALABRUTINIB PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Witzig, T.; Maddocks, K.; de Vos, S.; More

HemaSphere. 3(S1):387-388, June 2019.

PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

Babiker, H.; Milhem, M.; Aisner, J.; More

HemaSphere. 3(S1):799, June 2019.

Author:
Eder, T.
Author:
Edesa, W.
Author:
Edwards, K.
Author:
Eek, D.
Author:
Efebera, Y.A.

PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

Pour, L.; Efebera, Y.A.; Granell, M.; More

HemaSphere. 3(S1):257-258, June 2019.

Author:
Efeyan, A.

PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Kumar, E.; Korfi, K.; Bewicke-Copley, F.; More

HemaSphere. 3(S1):209, June 2019.

Author:
Efficace, F.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

Author:
Efimov, G.

PB2328 CMV-SPECIFIC T-CELL RECONSTITUTION AS A KEY FACTOR FOR IDENTIFICATION OF CANDIDATES FOR CMV-SPECIFIC LYMPHOCYTES INFUSION

Dmitrova, A.; Shmarov, V.; Drokov, M.; More

HemaSphere. 3(S1):1037, June 2019.

Author:
Efira, A.

PF694 TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM

Janssens, A.; Beguin, Y.; Lambert, C.; More

HemaSphere. 3(S1):301, June 2019.

Author:
Efobi, C.
Author:
Efremova, E.

PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3(S1):494, June 2019.

Author:
Egle, A.

PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3(S1):695-696, June 2019.

Author:
Egorova, E.

PS1104 EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3(S1):500, June 2019.

Author:
Egyed, M.

PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL

Röth, A.; Nagy, Z.; Peffault de Latour, R.; More

HemaSphere. 3(S1):125-126, June 2019.

PS1457 MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3(S1):670-671, June 2019.

Author:
Ehara, H.
Author:
Ehinger, M.

PF376 DIFFERENTIAL GENOMIC AND TRANSCRIPTOMIC EVENTS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA

Klintman, J.; Stamatopoulos, B.; Ridout, K.; More

HemaSphere. 3(S1):139-140, June 2019.

Author:
Ehninger, G.

PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY

Voso, M.T.; Larson, R.A.; Prior, T.; More

HemaSphere. 3(S1):79-80, June 2019.

PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3(S1):81-82, June 2019.

PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3(S1):436, June 2019.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

Author:
Ehrenfeld, S.
Author:
Eich, H.

S819 PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY

Fuchs, M.; Goergen, H.; Kobe, C.; More

HemaSphere. 3(S1):362, June 2019.

Author:
Eichenauer, D.

PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I)

Tresckow, B. von; Hüttmann, A.; Vucinic, V.; More

HemaSphere. 3(S1):565, June 2019.

Author:
Eichhorst, B.

S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3(S1):4, June 2019.

S106 HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3(S1):4-5, June 2019.

S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3(S1):26-27, June 2019.

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Rhodes, J.; Sail, K.; Sarraf Yazdy, M.; More

HemaSphere. 3(S1):142, June 2019.

PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY

Wu, J.; Bolen, C.; Seymour, J.F.; More

HemaSphere. 3(S1):508-509, June 2019.

Author:
Eichinger, S.
Author:
Eidelman, L.A.

PF334 EPIDURAL/SPINAL ANESTHESIA IN PREGNANT JEWISH ASHKENAZI WOMEN HETEROZYGOTES FOR FACTOR XI DEFICIENCY, A SINGLE CENTER PROSPECTIVE STUDY

Shacham Abulafia, A.; Yaniv, Y.; Steimatzky, A.; More

HemaSphere. 3(S1):119, June 2019.

Author:
Einsele, H.

PF155 COMBINATION OF FLOTETUZUMAB, A CD123 X CD3 BISPECIFIC DART® MOLECULE, AND BLINATUMOMAB, A CD19 X CD3 BITE MOLECULE, TO PREVENT ANTIGEN ESCAPE IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Lukic, D. Slavkovic; Duell, J.; Davidson-Moncada, J.; More

HemaSphere. 3(S1):29-30, June 2019.

S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3(S1):365, June 2019.

PS1001 HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3(S1):450, June 2019.

PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3(S1):695-696, June 2019.

Author:
Eisa, N.
Author:
Eischer, L.
Author:
Eisele, F.
Author:
Eisen, M.

PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

Roussel, M.; Moreau, P.; Attal, M.; More

HemaSphere. 3(S1):630, June 2019.

Author:
Eisfeld, A.-K.

PF232 PROGNOSTIC IMPACT OF THE 2017 EUROPEAN LEUKEMIANET (ELN) CLASSIFICATION OF YOUNGER ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED ON CANCER AND LEUKEMIA GROUP B (CALGB)/ALLIANCE PROTOCOLS

Bill, M.; Mrózek, K.; Eisfeld, A.-K.; More

HemaSphere. 3(S1):68-69, June 2019.

Author:
Eiznhamer, D.

PS1533 KD025–208: A PHASE 2A TRIAL OF KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) – UPDATED SAFETY AND EFFICACY

Salhotra, A.; Zoghi, B.; Essell, J.; More

HemaSphere. 3(S1):707-708, June 2019.

Author:
ejiofor, O.
Author:
Ekaterina, P.

PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3(S1):81-82, June 2019.

Author:
Eksmond, U.

PS1334 THERAPEUTIC RESPONSE OF MYELODYSPLASTIC SYNDROMES TO EPIGENETIC DRUGS INDEPENDENTLY OF ENDOGENOUS RETROELEMENT MODULATION

Kordella, C.; Kazachenka, A.; Lamprianidou, E.; More

HemaSphere. 3(S1):609, June 2019.

Author:
Ekushov, K.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

PS1077 EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP

Wudhikarn, K.; Bunworasate, U.; Julamanee, J.; More

HemaSphere. 3(S1):488, June 2019.

Author:
El Ashkar, S.
Author:
El Beshlawy, A.

S147 RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE

Vichinsky, E.; Hoppe, C.C.; Ataga, K.I.; More

HemaSphere. 3(S1):25-26, June 2019.

Author:
El Chazli, Y.
Author:
El Farra, A.
Author:
el Fassi, D.

S1609 THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Knudsen, T.A.; Lund Hansen, D.; Frans Ocias, L.; More

HemaSphere. 3(S1):741-742, June 2019.

Author:
El Fatmi, R.